T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?

Abstract:

:Introduction: Severe sickle cell disease is associated with progressive end-organ damage and early mortality in adults. While allogeneic hematopoietic cell transplant from a matched related donor is curative, the vast majority of patients do not have a compatible sibling. Accordingly, platforms using haploidentical donors have been developed, which provide near-universal availability. Areas covered: This review focuses on the two commonly used approaches for haploidentical hematopoietic transplants, namely T-cell deplete and T-cell replete, each of which is associated with unique benefits and drawbacks. The purpose of this paper is to facilitate individualized decision-making for patients and providers by reviewing the pros- and cons of these differing approaches. Expert opinion: Individuals with sickle cell disease eligible for a hematopoietic cell transplant can be considered based on recent results. Comparable outcomes are seen with T-cell deplete and T-cell replete approaches. The choice depends largely on institutional preference.

journal_name

Expert Rev Hematol

authors

Patel DA,Akinsete AM,Connelly JA,Kassim AA

doi

10.1080/17474086.2019.1642103

subject

Has Abstract

pub_date

2019-09-01 00:00:00

pages

733-752

issue

9

eissn

1747-4086

issn

1747-4094

journal_volume

12

pub_type

杂志文章,评审
  • Optimal treatment for relapsing patients with Hodgkin lymphoma.

    abstract::Relapsed or refractory classical Hodgkin lymphoma (HL) remains a therapeutic challenge. Patients with relapsed HL should be identified according to their prognostic factors at relapse (duration of remission and extranodal disease or stage). Patients with refractory disease, defined as progression during induction trea...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.12

    authors: Sibon D,Brice P

    更新日期:2009-06-01 00:00:00

  • Considerations when restarting anticoagulants in patients with atrial fibrillation after bleeding.

    abstract::Introduction: Oral anticoagulants (OACs) are established treatments to reduce thromboembolic risk in patients with atrial fibrillation (AF). Due to their mechanisms of action, they are associated with increased bleeding risk. Evaluation with bleeding risk scores may be useful to identify patients at high risk. However...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1647779

    authors: Kozieł M,Ding WY,Kalarus Z,Lip GYH

    更新日期:2019-10-01 00:00:00

  • An update on biology, diagnosis and treatment of primary plasma cell leukemia.

    abstract:INTRODUCTION:Primary plasma cell leukemia (PPCL) is one of the most aggressive hematological malignancies. The prognosis of PPCL patients remains poor, although some improvements have been made in recent years. Areas covered: In this review recent clinical and biological advances in PPCL are reported. Some recommendati...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1598258

    authors: Musto P,Statuto T,Valvano L,Grieco V,Nozza F,Vona G,Bochicchio GB,La Rocca F,D'Auria F

    更新日期:2019-04-01 00:00:00

  • Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.

    abstract::Recent studies have identified recurrent mutations in genes that encode proteins crucial in the epigenetic regulation of gene transcription in hematologic malignancies. Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukem...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1144469

    authors: Hou HA,Tien HF

    更新日期:2016-05-01 00:00:00

  • Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered indolent lymphocytic malignancies, more often requiring active surveillance rather than intervention. Despite the indolent nature of CLL/SLL, treatment is likely indicated in a patients' lifetime. Recent changes in the t...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1270203

    authors: Tees MT,Flinn IW

    更新日期:2017-02-01 00:00:00

  • Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma.

    abstract:INTRODUCTION:Hodgkin's lymphoma (HL) is largely a curable disease with excellent prognosis. The standard of care in patients with relapsed disease has been to try salvage chemotherapy followed by an autologous stem cell transplantation (ASCT). Managing the patients who relapse after ASCT, is challenging. With the appro...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1449637

    authors: Kallam A,Armitage JO

    更新日期:2018-04-01 00:00:00

  • Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency.

    abstract::Tumor lysis syndrome (TLS) is a rare but potentially life-threatening complication of neoplasms, preferentially hematological malignancies. Well known since at least ninety years ago, this condition can be misdiagnosed and incorrectly managed due to rapid onset of symptoms, sometimes overlapping with cancer-derived cl...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1127156

    authors: Criscuolo M,Fianchi L,Dragonetti G,Pagano L

    更新日期:2016-01-01 00:00:00

  • Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.

    abstract::Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1142370

    authors: Figueiredo L,Cole PD,Drachtman RA

    更新日期:2016-03-01 00:00:00

  • Advances in fertility preservation of female patients with hematological malignancies.

    abstract:INTRODUCTION:The most common forms of hematological malignancies that occur in female reproductive years are lymphoma and leukemia. Areas covered: Several aggressive gonadotoxic regimens such as alkylating chemotherapy and total body irradiation are used frequently in treatment of lymphoma and leukemia leading to subse...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2017.1371009

    authors: Salama M,Isachenko V,Isachenko E,Rahimi G,Mallmann P

    更新日期:2017-11-01 00:00:00

  • Risk assessment of venous thromboembolism in hematological cancer patients: a review.

    abstract::Introduction: Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients. Nonetheless, patients with hematological cancers receive less attention as compared with their solid tumor counterparts regarding this potentially fatal complication.Areas covered: Risk factors that are associated wit...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1751608

    authors: Chan TS,Hwang YY,Tse E

    更新日期:2020-05-01 00:00:00

  • Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

    abstract:INTRODUCTION:Peripheral T cell lymphomas (PTCL) are a heterogenous group of lymphoproliferative disorders which are generally not curable with conventional chemotherapy and associated with inferior outcomes. Pralatrexate is a novel folate analog, the first FDA approved drug) for the treatment of relapsed/refractory (R/...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1756257

    authors: Jennifer C Z,Sara Mohamed J,Salma A,Francine F

    更新日期:2020-06-01 00:00:00

  • Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?

    abstract:INTRODUCTION:First and second generation tyrosine kinase inhibitors, represent a new, fully biologic and targeted approach to chronic lymphocytic leukemia and allowed to obtain high responses and acceptable tolerability even in elderly and high risk patients. On the other hand, prolonged experience with these agents ha...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1191943

    authors: Frustaci AM,Montillo M,Picardi P,Mazzucchelli M,Cairoli R,Tedeschi A

    更新日期:2016-07-01 00:00:00

  • Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient.

    abstract::The incidence of non-Hodgkin's lymphoma (NHL) is increasing among all age groups, with a median age at diagnosis of 67 years. With the increase in the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients is affected by ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.7

    authors: Ninan MJ,Morrison VA

    更新日期:2009-04-01 00:00:00

  • Iliopsoas hematomas in people with hemophilia: diagnosis and treatment.

    abstract:INTRODUCTION:Iliopsoas muscle hemorrhage in patients with hemophilia is a serious complication with relevant related morbidity. AREAS COVERED:A Cochrane Library and PubMed (MEDLINE) search of studies related to iliopsoas hematomas in hemophilia was analyzed. Pain in the hip joint area and femoral nerve involvement in ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1787146

    authors: Rodriguez-Merchan EC,De la Corte-Rodriguez H

    更新日期:2020-08-01 00:00:00

  • Treatment of hairy cell leukemia.

    abstract:INTRODUCTION:Purine analogs made dramatic improvements for patients with hairy cell leukemia (HCL), but patients often relapse, require multiple treatments, and may become refractory. Major developments in treatment of relapsed/refractory HCL occurred with discovery of disease biology. New agents increase the complexit...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1819231

    authors: Chihara D,Kreitman RJ

    更新日期:2020-10-01 00:00:00

  • The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.

    abstract::Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery. Due to the high incidence of venous thromboembolism in this setting, perioperative anticoagulation is the recommended approach for thromboprophylaxis. Low molecular weight heparin (LMWH), fondapar...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2013.853430

    authors: Rachidi S,Aldin ES,Greenberg C,Sachs B,Streiff M,Zeidan AM

    更新日期:2013-12-01 00:00:00

  • Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options.

    abstract:INTRODUCTION:Large granular lymphocytic leukemia (LGLL) is a low grade lymphoproliferative disorder characterized by the clonal proliferation of large granular lymphocytes (LGL) and recognised by the WHO. The diagnosis and management of these patients is challenging due to the limited information from prospective studi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1284585

    authors: Matutes E

    更新日期:2017-03-01 00:00:00

  • Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.

    abstract::In chronic lymphocytic leukemia (CLL), the most prevalent lymphoid malignancy in western countries, patients have a median age at diagnosis of 72 years. In the last few years, there has been remarkable progress in understanding the biology of CLL, the detection of molecular prognostic factors and the development of mo...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2013.814845

    authors: Molica S,Brugiatelli M,Morabito F,Ferrara F,Iannitto E,Di Renzo N,Capalbo S,Musto P,Di Raimondo F

    更新日期:2013-08-01 00:00:00

  • Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.

    abstract::Human acute myeloid leukemia is a heterogeneous disease and the effect of therapeutic targeting of specific molecular mechanisms will probably vary between patient subsets. Cell cycle regulators are among the emerging targets (e.g., aurora and polo-like kinases, cyclin-dependent kinases). Inhibition of communication b...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2015.1032935

    authors: Reikvam H,Hauge M,Brenner AK,Hatfield KJ,Bruserud Ø

    更新日期:2015-06-01 00:00:00

  • Mitochondria and Iron: current questions.

    abstract:INTRODUCTION:Mitochondria are cellular organelles that perform numerous bioenergetic, biosynthetic, and regulatory functions and play a central role in iron metabolism. Extracellular iron is taken up by cells and transported to the mitochondria, where it is utilized for synthesis of cofactors essential to the function ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1268047

    authors: Paul BT,Manz DH,Torti FM,Torti SV

    更新日期:2017-01-01 00:00:00

  • Analysis of Hb levels and degree of anemia in relation to genotype in 615 patients with hemoglobin H disease.

    abstract:OBJECTIVES:We analyzed hemoglobin (Hb) levels and degree of anemia in relation to genotype in patients with hemoglobin H (Hb H) disease, thereby providing a scientific basis for the prevention and treatment of Hb H disease in the Guangxi region of China. METHODS:Hb analysis was conducted in 615 patients using high per...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1803736

    authors: Luo S,Chen X,Chen L,Zhong Q,Wang Q,Xu Z,Huang J,Yan T,Tang N

    更新日期:2020-09-01 00:00:00

  • Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.

    abstract::Introduction: Secondary central nervous system lymphoma (SCNSL) is a potentially fatal event in the setting of aggressive Non-Hodgkin Lymphomas. Nowadays, despite of the very poor outcome of SCNSL, several studies are going to identify the high-risk patients' subgroup that could early develop this detrimental event an...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1643232

    authors: Santambrogio E,Nicolosi M,Vassallo F,Castellino A,Novo M,Chiappella A,Vitolo U

    更新日期:2019-09-01 00:00:00

  • Polyphosphates: a link between platelet activation, intrinsic coagulation and inflammation?

    abstract::Early evidence has already shown that activated platelets play a role in the intrinsic pathway of coagulation, but the mechanism remained unclear. The finding that the dense granules of platelets contain polyphosphate (polyP), which has procoagulant effects, resolved this missing link between activated platelets and c...

    journal_title:Expert review of hematology

    pub_type: 评论,杂志文章

    doi:10.1586/ehm.10.26

    authors: van der Meijden PE,Heemskerk JW

    更新日期:2010-06-01 00:00:00

  • Transfusion medicine in trauma patients: an update.

    abstract::In 2008, we reviewed the practical interface between transfusion medicine and the surgery and critical care of severely injured patients. Reviewed topics ranged from epidemiology of trauma to patterns of resuscitation to the problems of transfusion reactions. In the interim, trauma specialists have adopted damage cont...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.11.49

    authors: Murthi SB,Stansbury LG,Dutton RP,Edelman BB,Scalea TM,Hess JR

    更新日期:2011-10-01 00:00:00

  • Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.

    abstract::Indolent non-Hodgkin's lymphoma (iNHL) describes a group of B-cell lymphomas with a long median survival and a relapsing-remitting clinical course. Although existing treatments are initially effective, patients often relapse, demonstrating decreasing efficacy with successive treatment courses. Alternative treatments a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2015.1071663

    authors: Davies A

    更新日期:2015-10-01 00:00:00

  • Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?

    abstract::Introduction: Myelodysplastic Syndrome (MDS) represents a group of cancers characterized by abnormal blood cell formation and maturation, leading to various degrees of cytopenias and potential transformation to acute myeloid leukemia. Deletion of the long arm of chromosome 5 (del(5q)) is the most common clonal chromos...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1730806

    authors: Gorshein E,Weber UM,Gore S

    更新日期:2020-03-01 00:00:00

  • Lestaurtinib: a multi-targeted FLT3 inhibitor.

    abstract::Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for th...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2.1.17

    authors: Fathi AT,Levis M

    更新日期:2009-02-01 00:00:00

  • CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.

    abstract::Introduction: The genomic landscape of Waldenström macroglobulinemia (WM) is characterized by recurrent MYD88 (MYD88L265P) and CXCR4 mutations (CXCR4MUT), detected in 90% and 30% of cases, respectively. The role of CXCR4MUT in clinical features and outcomes to therapy in WM patients is evolving. Areas covered: We perf...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2019.1649132

    authors: Castillo JJ,Moreno DF,Arbelaez MI,Hunter ZR,Treon SP

    更新日期:2019-10-01 00:00:00

  • Initial treatment of transplant-ineligible patients in multiple myeloma.

    abstract::Over two-thirds of newly diagnosed multiple myeloma are over 65 years. The treatment goals for the non-transplant-eligible patients should be to prolong survival by achieving the best response, while ensuring quality of life. New upfront treatment combinations based on first generation of novel proteasome inhibitors a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.864230

    authors: Mateos MV,Leleu X,Palumbo A,San Miguel JF

    更新日期:2014-02-01 00:00:00

  • Diagnosis and management of catastrophic antiphospholipid syndrome.

    abstract:INTRODUCTION:Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening disease. In 1992, Asherson defined it as a widespread coagulopathy related to the antiphospholipid antibodies (aPL). CAPS requires rapid diagnosis and prompt initiation of treatment. Areas covered: This paper discusses all aspects of...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1300522

    authors: Carmi O,Berla M,Shoenfeld Y,Levy Y

    更新日期:2017-04-01 00:00:00